Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss

Andreas Fontalis, Eustathios Kenanidis, Rafail Angelos Kotronias, Afroditi Papachristou, Panagiotis Anagnostis, Michael Potoupnis & Eleftherios Tsiridis

Published online: 08 Apr 2019.

Submit your article to this journal ↗

View Crossmark data ↗

Taylor & Francis
Taylor & Francis Group

REVIEW

Check for updates

Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss

Andreas Fontalis[a,b], Eustathios Kenanidis[c,d], Rafail Angelos Kotronias[e], Afroditi Papachristou[f], Panagiotis Anagnostis[d,g], Michael Potoupnis[c,d] and Eleftherios Tsiridis[c,d]

[a]Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK; [b]Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, UK; [c]Academic Orthopaedic Unit, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, Greece; [d]Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI), Aristotle University of Thessaloniki, Thessaloniki, Greece; [e]Division of Cardiovascular Medicine, Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK; [f]Pharmacy Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; [g]Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynaecology, Aristotle University Medical School, Thessaloniki, Greece

ABSTRACT

Introduction: Pharmacological options to address the imbalance between bone resorption and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique biologic pathways such as the Wnt/β-catenin pathway have been targeted in the quest for new emerging therapeutic strategies.

Areas covered: This review provides an overview of existing pharmacotherapy for osteoporosis in women and explore state-of–the-art and emerging therapies to prevent bone loss, with an emphasis on the mechanism of action, indications and side effects.

Expert opinion: Bisphosphonates appear to be a reliable and cost-effective option, whereas denosumab has introduced a simpler dosing regimen and may achieve a linear increase in bone mineral density (BMD) with no plateau being observed, along with continuous anti-fracture efficacy. Abaloparatide, a parathyroid-hormone-related peptide (PTHrP)-analogue, approved by the FDA in April 2017, constitutes the first new anabolic osteoporosis drug in the US for nearly 15 years and has also proven its anti-fracture efficacy. Romosozumab, a sclerostin inhibitor, which induces bone formation and suppresses bone resorption, has also been developed and shown a significant reduction in fracture incidence; however, concerns have arisen with regard to increased cardiovascular risk.

1. Introduction

Osteoporosis is a metabolic bone disease characterized by an imbalance between bone resorption and accrual, resulting in microarchitectural disruption, reduced bone mineral density (BMD) and skeletal fragility [1]. Fragility fractures are common in the osteoporotic population and occur from forces not ordinarily resulting in fracture. The most common sites are the vertebral column, hip and wrist; however, fragility fractures of the humerus, pelvis and ribs are not uncommon [1].

Over the past decades, several medications with different mechanisms of action have been employed for the treatment and prevention of osteoporosis. Current pharmacological options include anti-resorptive and osteoanabolic agents as well as drugs with dual action. Anabolic agents aim to inverse the imbalance in bone remodeling by stimulating bone formation, therefore increasing BMD; they are represented predominantly by teriparatide and abaloparatide.

On the other hand, anti-resorptive medications try to address the imbalance between bone resorption and accrual. They aim to inhibit bone resorption by decreasing bone turnover or disrupting osteoclast proliferation and maturation and include five principal classes of agents; bisphosphonates,

selective estrogen receptor modulators (SERMs), estrogens, denosumab (monoclonal antibody) and calcitonin [2].

Most of the current pharmacological strategies are principally based on bone anti-resorptive agents. In clinical practice, bisphosphonates (alendronate, risedronate, ibandronate, zole-dronic acid) are utilized as first-line treatments since they constitute cheap and reliable agents, which are effective in reducing vertebral, non-vertebral and hip (except for ibandronate) fracture risk [3]. Denosumab is an anti-RANKL monoclonal antibody suppressing bone resorption with high and continuous anti-fracture efficacy [3,4]. Selective estrogen receptor modulators (SERMs) are synthetic non-steroidal agents which have demonstrated varying estrogen agonist and antagonist activities in different tissues as well as antifracture efficacy [3]. On the other hand, anabolic agents are reserved for high fracture risk individuals, preventing both vertebral and non-vertebral fractures [5]. They are predominantly represented by teriparatide, a human recombinant parathyroid hormone (PTH), and abaloparatide, a synthetic PTH-related peptide (PTHrP) analogue.

New emerging therapeutic strategies target unique biologic pathways such as the Wnt/β-catenin pathway [6].These strategies have the potential to substantially decrease bone

resorption and be more effective in fracture reduction in osteoporotic patients.

This review maps out existing pharmacotherapy for osteoporosis in women with an emphasis on the mechanism of action and the state-of-the-art therapies to prevent bone loss. Our review also explores emerging pharmacological strategies and touches upon the future direction in the field.

1.1. Anti-resorptive medications

1.1.1. Bisphosphonates

Bisphosphonates are structurally linked to inorganic pyrophosphate, a naturally occurring compound consisting of two phosphate groups [7].Like pyrophosphate, bisphosphonates have demonstrated a very high affinity for hydroxyapatite crystals and are predominantly embedded in sites of augmented skeletal turnover [7].

First generation bisphosphonates (etidronate, clodronate, tiludronate) are characterized by non-nitrogen containing agents and have a distinct mechanism by which osteoclast apoptosis is fostered. Owing to their structural similarity to pyrophosphate, they become embedded in adenosine triphosphate (ATP) molecules following osteoclast-mediated uptake [8]. Consequently, a high concentration of the above-mentioned ATP analogues exhibits a cytotoxic effect on osteoclasts, eventually promoting osteoclast apoptosis.

The second and third generation of bisphosphonates utilized for the treatment and prevention of osteoporosis (alendronate, pamidronate, ibandronate, risedronate and zoledronic acid) share a structural similarity since they have nitrogen-containing R^2 side chains [7]. Their anti-resorptive effect results from the inhibition of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonic acid pathway. The mevalonate pathway is critical in regulating the production of isoprenoid lipids and sterols employed for the isoprenylation (post-translational modification) of GTP-binding proteins which play central roles in osteoclast function

[7,9,10]. As a result, their anti-resorptive potency lies in their ability to promote osteoclast apoptosis.

Bisphosphonate potency is largely dependent on their activity to inhibit farnesyl pyrophosphate synthase; the rank order of potency is zoledronate>risedronate≫ ibandronate > alendronate [11]. Bisphosphonates also differ in their bond strength to the mineral matrix, with zoledronic acid demonstrating the highest affinity to hydroxyapatite crystals [7], followed by alendronate, ibandronate and risedronate [12]. Biochemical markers of bone turnover that reflect the activity of bone cells and hence can be utilised to measure bisphosphonate efficacy in the clinical setting, include bone resorption markers; mainly the degradation products of type I collagen, serum C-telopeptide of type I collagen (sCTX-1) and urine (uNTX) or serum N-terminal telopeptide (serum NTX), as well as bone formation markers, such as the isoenzyme of alkaline phosphatase and serum type 1 procollagen (C-terminal or N-terminal) peptides C1NP or P1NP, respectively.

Owing to their unique mechanism of action and long halve-lives, bisphosphonates are accumulated and released from the skeleton for a long time after treatment is ceased. Notwithstanding technical challenges in estimating bisphosphonate levels in serum and urine, studies have reported a slow elimination phase with an estimated biologic half-life greater than ten years following intravenous administration of high doses of alendronate [13]. The fact that they can protect an individual for an additional 3–5 years [10] has been the basis of advocating a "drug holiday'' after 5–10 years of continuous administration [14]. However, recommendations are to be individualized to each patient's clinical picture. As reflected by international guidelines, such as those released by the American Society for Bone and Mineral Research (ASBMR), and the European Menopause and Andropause Society [15] risk should be stratified in women following five years of alendronate or three years of intravenous bisphosphonate therapy [16]. High-risk postmenopausal women should continue BP therapy since the benefit deriving from fracture risk reduction greatly outweighs the risk of serious adverse events. For women considered of low risk, a 'drug holiday' can be considered, with periodic risk assessment [16].

All currently approved bisphosphonates are indicated for osteoporosis treatment and fracture prevention; namely reducing the incidence of spinal fractures. Alendronate, risedronate and zoledronic acid have also demonstrated efficacy in preventing hip and non-vertebral fractures, contrary to ibandronate [17]. Their indications and approved dosing can be found in Table 1.

A recently published systematic review and network meta-analysis encompassing thirty-six primary studies concluded that zoledronic acid demonstrated comparative efficacy in preventing vertebral and non-vertebral fractures, whereas both alendronate and zoledronic acid were the most effective in preventing hip fractures [25]. Results were concordant with a previously published comparative network meta-analysis reporting that zoledronic acid showed the highest overall probability of protecting from any fracture [26].

The commonest side effects include gastrointestinal irritation and acute phase reaction with intravenous administration,

Table 1. Approved dosing and fracture risk reduction reported in key and registration trials.

Drugs	Prevention of osteoporosis	Treatment of osteoporosis	Relative risk reduction for vertebral and nonvertebral fractures		Approved dosing
			Spine	Nonvertebral	
Alendronate [18,19]	+	+	47%	48%–51%	35mg[#]–70 mg weekly* (oral)
Risedronate [19–21]	+	+	41%	30%–39%	150 mg monthly*,[#] (oral)
					3 mg every three months* (intravenous)
Ibandronate [17,19]	+	+	62%	NS	5 mg daily*,[#] (oral)
					35 mg weekly*,[#] (oral)
					150mg monthly*,[#] (oral)
Zoledronic acid [19,22]	+	+	70%	25%	5mg yearly* (intravenous)
					5mg every two years[#] (intravenous)
Denosumab [41]	+	+	68%	20%	60mg 6-monthly*,[#] (subcutaneous)
Raloxifene [23,65]	+	+	35%–42%	NS	60mg daily*,[#] (oral)
Abaloparatide [84]	-	+	86%	43%	80 μg daily* (subcutaneous)
Teriparatide [24]	-	+	66%	50%	20 μg daily* (subcutaneous)

[#]prevention dose, *treatment dose, NS: Not Significant
Relative risk reduction reported for bisphosphonates pertain to data from randomized trials with at least 3 years of bisphosphonate administration.

although they are frequently mild in severity [12]. Uncommon side effects involve musculoskeletal pain, while it has been suggested, that albeit rare, osteonecrosis of the jaw (ONJ) and atypical femoral bone fractures (AFFs) represent serious complications associated with long-term use of nitrogen bisphosphonates. However, the incidence of AFFs among patients receiving bisphosphonates is low, and a causal relationship has yet to be established. Owing to their rarity, none of the long-term trials was statistically powered to evaluate differences in the incidence of ONJ or AFFs.

1.1.2. Denosumab

Osteoclasts originate from cells of the monocyte/macrophage lineage upon stimulation of two major modulators of osteoclast formation, the monocyte/macrophage colony-stimulating factor (M-CSF) and the receptor activator of NF-κB ligand (RANKL), a type I transmembrane protein [27]. Other regulatory molecules involve cytokines and hormones such as PTH, prostaglandin E2, calcitriol, thyroxine, and interleukin-1 (IL-1) [28–30]. M-CSF binds to its receptor on the osteoclast, c-fms (colony-stimulating factor 1 receptor), a transmembrane tyrosine kinase-receptor, ameliorating survival and proliferation of osteoclast precursors [27,31]. However, the receptor activator of nuclear factor-κB ligand (RANKL) is considered to represent the primary osteoclast differentiation factor. RANKL, a type II transmembrane protein [32], belongs to the TNF (Tumour Necrosis Factor) ligand family and binds to RANK to stimulate the differentiation and multiplication of osteoclasts [32,33]. In more detail, RANKL activates c-Fos, a transcription factor, that in turn precipitates a chain reaction eventually leading to osteoclast differentiation and apoptosis inhibition [32].Osteoprotegerin (OPG) is a soluble decoy receptor expressed in osteoblasts and other tissues, such as spleen and bone marrow [32]. The role of the OPG in the bone resorption regulation lies in its ability to inhibit RANK/RANKL interaction, therefore inhibiting osteoclast differentiation and protecting from excessive bone resorption. Therefore, OPG and RANKL are competitors in the molecular milieu, with high OPG concentrations exerting an inhibitory effect on the RANK–RANKL signalling pathway.

Denosumab is an IgG2 monoclonal antibody that suppresses bone resorption by mimicking the action of OPG in bone microenvironment and has been approved for fracture treatment and prevention of osteoporosis. In particular, denosumab is used for preventing spinal, hip and non-vertebral fractures. Denosumab binds to RANKL preventing its binding to RANK, hence reducing osteoclast proliferation, survival and bone resorption. Its chemical structure consists of four chains; two heavy chains consisting of 448 amino acids with four intramolecular disulfides and two light chains consisting of 215 amino acids [34]. Alike other monoclonal antibodies, denosumab has demonstrated non-linearity in its pharmacokinetics dependent on the dose. It is characterized by a unique biochemical profile of prolonged absorption and β phase, whereas the terminal phase is more rapid [34].

A pooled analysis of 22,944 serum denosumab concentrations in 1,564 subjects defined the subcutaneous bioavailability of denosumab to be 64% and the RANKL degradation rate 0.00148 h^{-1} [35]. The first-order absorption rate constant (k_a)utilized to characterize absorption was determined to be $k_a = 0.00883$ h^{-1} [35]. Dosing adjustment based on the patient's baseline characteristics is not deemed necessary as the non-linear pharmacokinetic profile is probably attributed to RANKL binding [35]. Pharmacokinetic and pharmacodynamic properties of different antiresorptive agents are presented in Table 2.

Denosumab is administered subcutaneously at a dose of 60mg once every six months. Available higher-level research evidence supports the superiority of denosumab against other anti-osteoporotic drugs. In a dose-response-based meta-analysis encompassing 142 RCTs, denosumab demonstrated greater BMD gains compared with other drug classes; namely alendronate, risedronate, zoledronic acid, ibandronate, raloxifene and calcitonin [36]. In concordance, a recently published meta-analysis involving 2,968 non-naïve patients reported superiority of denosumab in augmenting BMD at all skeletal sites measured compared with other anti-osteoporotic drugs [37].Owing to its dosing frequency and regimen simplicity, denosumab has also achieved higher persistence rates compared with bisphosphonates [38–40].

A unique characteristic of denosumab is that no apparent plateau in BMD gains has been demonstrated in the numerous trials so far. The FREEDOM (Fracture Reduction Evaluation of

Table 2. Pharmacokinetic and pharmacodynamic properties of different antiosteoporotic agents.

Antiresorptive medications	Mechanism of Action	Absorption characteristics	Elimination half-life ($t_{1/2}$)	Protein binding	Systemic clearance
Alendronate (Fosamax ®)	Bisphosphonates acting primarily as FPPS inhibitors	Oral bioavailability: 0.59%–0.78% in fasted state. Reduced by ~60% after caffeinated drinks or orange juice	72hrs- (following single i.v dose)–10 years (terminal $t_{1/2}$)	~78% in human plasma	< 200 ml/min.
Ibandronate Risedronate (Actonel ®)		Oral bioavailability: ~0.6% in fasted state Oral bioavailability: 0.63% in fasted state	Terminal 10-72hrs ~1.5hrs	85%–87% in human plasma ~24%	84–160 ml/min ~122 ml/min
Zoledronic acid		Oral bioavailability: ~1% in fasted state	0.24–1.87hrs (following single i.v dose) 146hrs (terminal $t_{1/2}$)	~56%	22 –143 ml/min
Calcitonin	Inhibitor of osteoclast activity	Oral bioavailability: 0.45–1.4%.	50–80min	30–40%	6–9 ml/min
Denosumab (Prolia ®)	IgG2 monoclonal antibody inhibiting RANKL	Subcutaneous bioavailability: ~64%	~25–30 days	Not applicable	Non-specific, linear pathway of elimination via the reticuloendothelial system and/or proteolysis from the liver.
Odanacatib*	CTSK inhibitor	Absolute oral bioavailability: 30% at 50 mg and 70% at 10 mg	66–93 hrs	~97.5%	13ml/min
Romosozumab*	Sclerostin inhibitor	Absolute subcutaneous bioavailability: 88%	11–18days and 6–7days (biphasic elimination)	Not applicable	No-linear elimination pharmacokinetics. Elimination occurs via the reticuloendothelial system and/or proteolysis from the liver
Raloxifene (Evista ®)	SERMs	Oral bioavailability: ~60%	~27.7hrs	98–99% in human plasma	~5 days for total dose to be excreted in faeces (<6% of the total dose is eliminated in urine)
Bazedoxifene		Oral bioavailability: ~6%	~30hrs	Undetectable	Apparent clearance 4 to 5 l/h/kg. Elimination predominantly in faeces (<1% excreted in urine)
Lasofoxifene		Oral bioavailability: ~6%	~6 days	Undetectable	~24 days (for 72% of total dose to be eliminated). Less than 2% excreted in urine
Teriparatide	Anabolics	Subcutaneous bioavailability: ~95%	~1 hr	Not applicable	Hepatic elimination c and extra-hepatic clearance occurs. Data suggest approximately 62 L/hr in women and 94 L/hr in men.
Abaloparatide		Absolute subcutaneous bioavailability: 36% at 80mcg	1.7hrs	~70%	Elimination by renal clearance. No specific excretion studies have been performed to date.

*reported data
SERMs: Selective estrogen receptor modulators, CTSK: Cathepsin K, RANKL: Receptor activator of nuclear factor kappa-B ligand, FPPS: farnesyl pyrophosphate synthase

Table 3. Most common adverse reactions and precautions for use for the different types of antiosteoporotic drugs currently licensed in the UK.

Drug Class	Most common adverse reactions experienced*	Warnings & Precautions for use*
Bisphosphonates SERMs Denosumab Osteoanabolics	Musculoskeletal (bone, muscle or joint) pain, headache, dizziness, Gastrointestinal (GI) disturbances (abdominal pain, dyspepsia, flatulence, constipation, oesophageal ulcer, diarrhoea) Headache, migraine, vasodilation (hot flushes), GI symptoms (nausea, vomiting, abdominal pain, dyspepsia), rash, leg cramps, mild breast symptoms (pain, enlargement and tenderness), flu syndrome, peripheral oedema, hypertension Abdominal discomfort, cataracts, GI symptoms (constipation, diarrhoea) dyspnoea, eczema; hypocalcaemia, hypophosphataemia, musculoskeletal pain, osteonecrosis of the jaw; pain in extremity, rash; sciatica, sweating, infections (upper respiratory tract infection, urinary tract infection) Anaemia, Hypercholesterolaemia, depression, dizziness, vertigo, headache, sciatica, syncope, palpitations, hypotension, dyspnoea, fatigue, chest pain, asthenia, increased sweating, GI symptoms (Nausea, vomiting, hiatus hernia, gastro-oesophageal reflux disease), muscle cramps, mild and transient injection site events, including pain, swelling, erythema, localised bruising, pruritus and minor bleeding at injection site.	• Osteonecrosis of the jaw • Osteonecrosis of the external auditory canal • Atypical fractures of the femur • GI irritation • Hypocalcaemia • Renal Toxicity • venous thromboembolic events • coronary events (myocardial infarction, stroke) • increase in serum triglycerides (in patients with a history of oral oestrogen-induced hypertriglyceridemia) (>5.6 mmol/l) • Atypical femoral fractures • Hypocalcaemia (fatal cases reported) • Osteonecrosis of the jaw • Small and transient elevations of serum calcium concentrations post teriparatide injection • Exacerbation of urotheliasis • Orthostatic hypotension

*Described as common (≥1/100, < 1/10) and with an overlapping incidence amongst all the drugs in the studied class. Individual agents within the same class may have more side effects established and/or precautions for use which are not listed in this table.
SERMs: Selective estrogen receptor modulators

Denosumab in Osteoporosis Every Six Months) was the largest phase III registration trial for studying denosumab. It included of 7,808 postmenopausal women with lumbar spine BMD T-scores<2.5 that were randomly assigned to 60 mg denosumab/6 monthly or placebo for three years [41].The reported results unveiled a relative risk reduction (RRR) in the incidence of new vertebral fractures of 68%, p < 0.0001, while denosumab also reduced hip and non-vertebral fractures (RRR 40%, *p* < 0.04 and RRR 20%, *p* < 0.01) [41].Recently published results revealed that ten years of denosumab administration resulted in a linear increase in lumbar spine BMD accounting for a cumulative 21.7% increase [42].

Unlike bisphosphonates, denosumab is not characterised by a long biologic half-life nor is it incorporated into the bone; hence its antiresorptive effect ceases after suspension of treatment. Several reports have described cases of multiple vertebral fractures upon discontinuation of denosumab, raising concerns about a rebound in bone turnover and BMD losses [43–46]. Following a systematic review of reported case series and a renewed analysis of the FREEDOM and FREEDOM Extension Trial, recommendations were issued by a working group formed by the European Calcified Tissue Society (ECTS); re-stratification of risk should be performed after five years of administration and denosumab cessation should not be considered without alternative osteoporosis treatment [47].

Owing to the drug's pharmacological mechanism of action, concerns had been raised regarding the potentiality to provoke immunosuppression and immune system dysfunction. According to post-market safety surveillance reports, serious adverse reactions involved AFFs, ONJ, severe symptomatic hypocalcemia (SSH) and anaphylaxis (Table 3) [48]. Four cases were adjudicated as consistent with AFF while another 32 were consistent with the ONJ, with the exposure to denosumab estimated at 1,252,566 patient-years. Anaphylaxis occurred in five patients with no fatal outcomes reported. In eight study subjects, SSH was evident, with chronic kidney disease identified as a risk factor in this group [48]. Of note, none of the existing RCTs has reported a higher incidence of AFF or ONJ with the administration of denosumab and a causal relationship has not been established yet.

1.1.3. Selective estrogen receptor modulators (SERMS)
Estrogen receptors are found both in osteoclasts and osteoblasts, contributing to bone remodelling regulation. It has been established that estrogen deficiency increases bone resorption [49]. The exact mechanism seems to be mediated by T-cells, which in an estrogen deplete-state, increase the secretion of tumor necrosis factor (TNF)–alpha, interleukin-6 (IL-6) and IL-1 [29,30,50]. These cytokines, in turn, enhance the production of RANKL and M-CSF [51] amplifying osteoclastogenesis and osteoclast differentiation. It has also been postulated that the intestinal microbiome plays an important role in the mechanism by which estrogen deficiency causes bone loss. Recent investigations unveiled that the intestinal flora as well as an increase in the gut permeability can induce inflammatory pathways that sequentially result in trabecular bone loss [52].

Overcoming estrogen depletion emerged as another promising pharmacological target for the treatment and prevention of osteoporosis in post-menopausal women. Over the past decade, SERMs have been intensively studied [53]. They are synthetic, structurally different non-steroidal agents that have tissue-specific estrogen receptor agonist or antagonist activity in varying magnitudes. Their biological activity is mainly attentive to ER-alpha (ER-α) and ER-beta (ER-β) subtypes for the ER family. ER-α is expressed in a greater tissue variety and is considered to be the principle ER expressed in bone tissue, whereas ER-β is mainly expressed in the ovaries, prostate and lungs [54]. SERMs exhibit different affinity properties, resulting in unique agonist/antagonist effects [55–57]. Notably, most SERMS exert estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. In particular, by binding to estrogen receptors in bone tissues, SERMs interfere with bone homeostasis by down-modulating the activity of osteoclasts in a transforming growth factor-β3-dependent manner leading to reduced bone resorption [58].

SERMs have been studied as a subject of great scientific interest, due to their theoretical ability to retain the beneficial effects of oestrogens while eliminating unwanted side-effects related to oestrogen-receptor binding in non-targeted tissues. There are two main classes of agents used in clinical practice: a) the triphenylethylene derivatives, tamoxifen and toremifene, which are employed for the treatment of breast cancer and b) raloxifene (benzothiophene derivative), bazedoxifene and lasofoxifene (naphthalene derivative), which are indicated for the prevention and treatment of osteoporosis [59].

Raloxifene, a second-generation SERM, has been established as a third-line treatment for the secondary prevention of osteoporotic fragility fractures in postmenopausal women [60], excluding hip and non-vertebral fractures. Further development of SERM compounds, led to another generation of SERMs with comparable chemical and molecular structure to raloxifene but optimised side-effect profile named as bazedoxifene (TSE-424) and lasofoxifene (CP-336156) [53].

In the 1990s, the idea of combining bazedoxifene with conjugated estrogen was introduced aiming to achieve greater estrogenic and anti-estrogenic effects than either of the components alone. The latter combination resulted in the introduction of a new classification named as tissue selective estrogen complex (TSEC) [61,62]. Phase III RCTs exploring the combination of bazedoxifene with conjugated estrogens in healthy post-menopausal women with osteoporosis have confirmed the aforementioned superiorities, showing improvement in vasomotor symptoms and little or no stimulation of breast or endometrium oestrogen receptors (ER) [63,64].

The incidence of new vertebral fractures in post-menopausal women with diagnosed osteoporosis (n = 7,492), was significantly lower with bazedoxifene 20 mg (2.3%), bazedoxifene 40 mg (2.5%), than placebo (4.1%), and comparable to raloxifene 60 mg (2.3%), as demonstrated by a 3-year phase III RCT [65]. Interestingly, secondary endpoints of the above study showed that bazedoxifene (with or without conjugated estrogen) also had a positive effect on lumbar spine BMD in healthy post-menopausal women, compared with placebo groups, which was maintained after five to seven years of treatment [66]. Bazedoxifene has been approved by the European Medicines Agency (EMA) for the treatment of osteoporosis in 2009, while the U.S. Food and Drug Administration (FDA) granted approval of bazedoxifene with conjugated estrogen as a combinational drug in 2013, for the prevention of post-menopausal osteoporosis and vasomotor symptomatology.

Lasofoxifene has been described as another 3rd generation SERM, with comparable clinical effects to bazedoxifene. Lasofoxifene demonstrates high-affinity selective binding to both ERα and ERβ receptors [67]. Unlike bazedoxifene, it is characterized by a remarkable oral bioavailability, which is attributed to increased resistance in intestinal wall glucuronidation [68,69]. Lasofoxifene has demonstrated linear pharmacokinetics over a wide dose range (from 0.01 to 100 mg/d), and interestingly a Cmax of ~ 6 hours. Elimination has also been studied, and terminal elimination half-life ($t_{1/2}$) has been estimated to be reached at day 6 [70].

Dosing regimens were compared in a phase II RCT were BMD increase was measured as a biomarker with both doses of lasofoxifene, compared with baseline (increases of 1.8% and 2.2% for 0.25 mg and 1.0 mg/day, respectively, $p \leq 0.05$), and with placebo (3.6% and 3.9% for 0.25 mg and 1.0 mg/day, respectively, $p \leq 0.05$) [69]. Lasofoxifene has been evaluated in multiple phase III clinical trials including the PEARL [71] (Postmenopausal Evaluation and Risk Reduction With Lasofoxifene), OPAL [72] (Osteoporosis Prevention and Lipid-Lowering study), CORAL [69] (Comparison of Raloxifene and Lasofoxifene trial), where it repetitively demonstrated an improvement in bone mass and a reduction in the risk of vertebral and non-vertebral fractures. As concluded after the completion of all the aforementioned trials, lasofoxifene, demonstrated a dose-related optimized side effect profile compared to placebo. The RRR in the absolute incidence of invasive breast cancer was 85% for 0.5 mg/day (p < 0.05), 21% for 0.25 mg/day (p > 0.1) and for the incidence of major coronary heart disease 1.8% for 0.5 mg/day p < 0.05 and 2.4% for 0.25mg/day p > 0.1 [73]. In line with the risk of deep vein thrombosis (DVT) pertaining to estrogen replacement regimens, lasofoxifene was associated with an approximately 2-fold increased risk of DVT, as evidenced by the findings of the PEARL study follow-up. In fact, pulmonary embolism occurred less frequently than deep vein thrombosis (0.2% vs. 0.8%, respectively) but was also significantly increased in patients treated with the active drug compared with placebo [hazard ratio (HR): 4.49, 95% confidence interval (CI), 0.97–20.79 for lasofoxifene 0.5 mg/d and HR: 5.98, 95% CI, 1.33–26.72 for lasofoxifene 0.25 mg/d] [74].

To date, the FDA has yet to approve the use of lasofoxifene following the last rejection in January 2009. Nevertheless, EMA approved its use for the treatment of osteoporosis-related fractures in post-menopausal women, the same year. This followed by a cessation of the validity of the marketing authorization in 2012 as lasofoxifene had not been marketed in Europe since its initial marketing authorization.

1.2. Anabolic agents

Anabolic agents stimulate bone formation and are represented predominantly by teriparatide, a human recombinant parathyroid hormone (PTH) containing the first 34 amino acids of the endogenous hormone, and abaloparatide, a synthetic PTH-related peptide (PTHrP) analogue. The biological activities of PTH and PTHrP analogues on bone are mediated through activation of the parathyroid hormone 1 receptor (PTH1R) [75], a G-protein coupled receptor with two different high-affinity conformations R0 and RG, expressed in a plethora of tissues including osteoblasts and osteoclasts [76]. Notably, osteoanabolic potency has been demonstrated only with intermittent administration of PTH and PTHrP analogues, whereas continuous stimulation of PTH1R has been shown to augment bone turnover and consequently result in bone resorption [77]. In the clinical setting, teriparatide has reportedly led in spine and hip BMD gains, vertebral and non-vertebral risk reduction in postmenopausal women, as well as in men and individuals suffering from glucocorticoid-induced osteoporosis [78]. The recent VERtebral fracture treatment comparisons in

Osteoporotic women (VERO) study demonstrated also that teriparatide was significantly more effective in reducing the incidence of new vertebral fractures compared with risedronate after 24 months of therapy in postmenopausal women with severe osteoporosis (defined as at least two moderate or one severe vertebral fracture and a BMD T-score of ≤-1.5) [79].

Abaloparatide is a selective activator of the PTH1R, exhibiting a higher selectivity to the RG confirmation than teriparatide [80]. The aforementioned difference is translated into a more transient response to ligand binding [76], hence minimizing stimulation of bone resorption. Initial attempts at evaluating the therapeutic potential of abaloparatide in animal studies unveiled encouraging results. Abaloparatide exhibited its osteoanabolic potency by increasing bone formation and BMD gains both in ovariectomized rats and ovariectomized cynomolgus monkeys [81,82]. Subsequently, as the agent moved swiftly from animal to human trials, concordant results were reported. A phase II multicentre, double-blind, RCT investigated the efficacy and safety of various dosing regimens of abaloparatide, against teriparatide and placebo [83]. Upon comparison of abaloparatide with placebo, significant BMD gains were reported in total hip and lumbar spine with the 40- and 80-μg once daily regimens and in femoral neck BMD with the 80-μg regimen. Notably, abaloparatide was superior to teriparatide in augmenting total hip BMD [83].

With regard to clinically translatable outcomes, the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) Trial, a phase III, double-blind RCT, evaluated the effect of abaloparatide, teriparatide and placebo on the incidence of new vertebral fractures and BMD changes [84]. Both active agents demonstrated superiority against placebo in reducing fractures and augmenting BMD at all skeletal sites studied. When compared with teriparatide, the 80-μg regimen demonstrated no difference concerning efficacy endpoints, albeit the incidence of hypercalcemia was lower [84].

Finally, abaloparatide received approval for the treatment of postmenopausal osteoporosis by the FDA in April 2017 constituting the first new anabolic osteoporosis drug in the US for nearly 15 years [85].Of note, the European Medicines Agency (EMA) has yet to approve abaloparatide for the treatment of postmenopausal osteoporosis amid concerns regarding the efficacy of the drug in preventing of non-vertebral fractures and adverse cardiac events.

Interestingly, several RCTs have attempted to adjudicate the effect of combining PTH analogs with other active agents. When compared with alendronate and PTH monotherapy, the combination of both failed to show any additive BMD increase [86]. In contrast, the Denosumab and Teriparatide Administration (DATA) study proved combined denosumab and teriparatide therapy to be superior to either agent alone [87]. With regard to abaloparatide, an extension of the ACTIVE trial was designed to assess the effect of the concurrent administration of alendronate in patients previously treated wither with abaloparatide or placebo. Results confirmed that gains in BMD and RRR increased even further for the abaloparatide/alendronate group compared with the placebo/alendronate group [88].

2. Sequential therapy

In general, the optimal therapeutic strategy after discontinuation of an anti-osteoporotic therapy, has yet to be established. However, several strategies have emerged and are presented below.

2.1. Anti-resorptive after osteo-anabolic therapy

Sequential anti-resorptive therapy, following the cessation of anabolic treatment has been evaluated by several studies. Alendronate may lead to a further increase in BMD, especially in the trabecular bone after completion of PTH (1–84) therapy [89]. Raloxifene also showed a beneficial effect in maintaining lumbar spine and increasing hip BMD after one year of teriparatide therapy [90]. The ACTIVExtend study was the first to assess the incidence of vertebral and nonvertebral fractures as the primary end-point, and also changes in BMD provoked by the sequential administration of an anti-resorptive agent (alendronate) after completion of the prespecified anabolic therapy. Abaloparatide followed by alendronate regimen effectively reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic fractures and increased BMD compared with placebo followed by alendronate [88].

2.2. Osteo-anabolic after anti-resorptive therapy

Twenty four months of teriparatide treatment significantly increased BMD in patients with and without previous antiresorptive administration [91,92]. Prior antiresorptive treatment, especially with agents of longer skeletal half-lives, may modestly blunt the expected BMD response to teriparatide but this has not been consistently replicated [92]. Romosozumab has also been evaluated in women previously treated with bisphosphonates for at least three years, in a head-to-head comparison with teriparatide. Romosozumab induced significantly greater hip BMD changes compared with teriparatide at one-year follow-up [93].

3. Emerging therapies

3.1. Anabolic agents with antiresorptive properties

Sclerostin–an osteocyte secreted glycoprotein coded for by the SOST gene [17q12-q21]–is a key regulator of osteoblast differentiation and function [6]. It binds to LRP-5/6 co-receptors preventing interactions between Wnt and its receptor, ultimately, leading to phosphorylation and degradation of ß-catenin [94]. As a result, Wnt target genes are not activated, downregulating the canonical Wnt singling pathway responsible for osteoblast differentiation, proliferation and function [95]. Notably, sclerostin has also been shown to promote osteoclast formation through a RANKL-dependent pathway [96]. From a clinical perspective, a study of patients with sclerostin genetic deficiency (van Buchem disease) found that patients had increased bone mass, strength and reduced fracture rates, corroborating the importance of sclerostin in

bone metabolism [97]. Another clinical and radiographical entity, caused by mutations in the SOST gene is sclerosteosis which is differentiated by van Buchem disease, by hand malformations and large stature [97]. The synthesis of molecular and clinical evidence rendered sclerostin blocking with a monoclonal antibody an attractive therapeutic target for osteoporosis.

Since then, three monoclonal antibodies have been developed: romosozumab (AMG-785), blosozumab (LY251546) and BPS804. Animal studies with romosozumab in ovariectomized rats and primates showed increases in bone mass and strength owing to the increased bone formation and reduced resorption [98,99]. Early human trials of romosozumab showed that the agent reaches peak serum concentration within a week, demonstrating a high binding affinity for sclerostin while displaying non-linear kinetics with biphasic elimination (t1/2 = 11–18 and 6–7 days) [100–102].

A Phase II RCT investigated the efficacy and safety of various dosing regimens of romosozumab against placebo, alendronate and teriparatide in post-menopausal women with low BMD [103]. When compared with placebo and active comparators, the 140 and 210 mg once monthly dosing regimens of romosozumab were significantly better in increasing lumbar spine, total hip and femoral neck BMD after 12 months of treatment. Indeed, bone formation biomarkers increased, albeit transiently (for ~2 months), with bone resorption assays demonstrating a sustained reduction of bone turnover for the duration of the trial. These results are suggestive of an uncoupling of bone remodelling such that osteoclast inhibition does not lead to reduced bone formation [95]. Similar results were also obtained in a placebo-controlled trial of blosozumab, further confirming the efficacy of sclerostin inhibition [104]. In a subgroup analysis of the phase II RCT, investigators assessed bone strength at the LS and TH by quantitative computed tomography (QCT) in patients receiving placebo, open-label teriparatide (20 μg daily) or romosozumab (210 mg monthly). Reportedly, romosozumab achieved significantly greater gains in volumetric BMD and strength compared to teriparatide [105].

Romosozumab is the first agent of its class to have progressed to phase III trials with the proposed regimen of 210mg subcutaneously injected once monthly. The STRUCTURE trial investigating romosozumab vs. teriparatide in high-risk for fracture postmenopausal women transitioning from a bisphosphonate showed superiority of romosozumab in hip, lumbar and femoral neck BMD gains (2.6% vs. −0.6%, 3.2% vs. −0.2%, 9.8% vs. 5.4%, p for all comparisons <0.0001) [93]. Similar significant hip, lumbar and femoral neck BMD gains in favour of romosozumab vs. placebo were noted in the BRIDGE study of men with osteoporosis [106].

In terms of the clinically relevant end-points of reduction in new vertebral fractures, romosozumab was superior to placebo in the ARCH and FRAME studies; results sustained after the addition of alendronate and denosumab respectively [107,108]. However, only ARCH showed a significant reduction in new vertebral, non-vertebral and hip fractures with romosozumab treatment. The discrepancy was cautiously attributed by the FRAME investigators to the recruitment of patients from a particular geographic region (Latin America) with a lower-than-expected non-vertebral fracture rate; effectively underpowering the trial for this end-point. Notably, a post-hoc analysis excluding patients from Latin America showed a significant reduction in new non-vertebral fractures favouring romosozumab [109].

Romosozumab was well-tolerated amongst recipients with discontinuation rates of 9.2%-11.2%, not significantly different from comparator group discontinuation rates whether active or placebo [93,109,110]. Regarding its safety, romosozumab inhibits sclerostin, whose secretion is confined mainly to the musculoskeletal system. However, the canonical Wnt signalling pathway is active in the cardiovascular and haematological systems [107,108,111]. Nonetheless, malignancy rates were similar in patients receiving romosozumab compared with control groups [109,110]. On the other hand, the signal with adjudicated serious adverse cardiovascular events is mixed; the FRAME study found no difference when romosozumab was compared to placebo (1.1% vs. 1.2% respectively) [109], though the ARCH and BRIDGE studies showed numerically higher serious adverse cardiovascular events with romosozumab when compared to alendronate (2.5% vs. 1.9%) and placebo (4.9% and 2.5%) respectively [106,110]. The latter underscored the FDA's request for data from all three romosozumab trials prior to its final licensing decision.

Although the exact pathogenetic mechanism has yet to be clarified, the loss of the sclerostin inhibitory role on vascular calcification and the potential cardioprotective role of alendronate have been proposed [106,110]. Romosozumab has recently received approval in Japan for the treatment of osteoporosis in patients at high fracture risk [112].

Nonetheless, the aforementioned results show that sclerostin inhibition is a potential therapeutic target for osteoporosis. To date, no phase III trials with blosozumab are being conducted while BPS804 is now undergoing phase IIa trials for osteogenesis imperfecta after withdrawing from the ever-competitive osteoporosis market.

4. Conclusions

Existing anti-resorptive pharmacotherapy strategies for osteoporosis in women encompass bisphosphonates, denosumab and SERMS. The third generation of bisphosphonates employed to date for the treatment of osteoporosis (alendronate, ibandronate, zoledronate, risedronate) appears to be a reliable and cost-effective option. However, concerns have been raised with respect to their link to ONJ and AFFs. In addition, poor compliance has been reported owing to complex dosing regimen, while long-term efficacy (> 5 years) is yet to be established. Denosumab introduced a novel mechanism of action by inhibiting the interaction between RANK and its ligand, therefore reducing osteoclast maturation, survival and bone resorption. Dosing frequency and regimen simplicity have contributed to higher persistence and compliance rates, whereas recently published data confirmed its unique characteristic of achieving a linear increase in BMD with no plateau being observed. Concerns regarding its association with ONJ and AFFs have not been confirmed as post market safety reports and higher-level evidence published failed to establish a causal relationship.

Teriparatide and abaloparatide constitute the only approved osteoanabolic therapies currently used in the treatment of osteoporosis. They have a vital role in the management of high fracture risk patients and can be combined or precede anti-resorptive therapy to maximize their effect. One should note though their limitations, of the parenteral delivery route and high cost [78].

Refined knowledge regarding the molecular mechanisms and pathophysiology underlying bone remodelling, resulted in the development of state-of-the-art pharmacotherapies with dual action. Indeed, the efficacy of sclerostin inhibition was proved since both romosozumab and blosozumab achieved a significant increase in BMD in phase II studies. Concordant results were reported in phase III trials, where romosozumab–the only agent of its class to progress to late-stage clinical development–augmented BMD in all skeletal sites measured. Of note, romosozumab has received approval in Japan for the treatment of osteoporosis in high fracture risk patients [112].

5. Expert opinion

Anti-resorptive drugs are used to suppress bone resorption and have spearheaded efforts to address the bone loss in osteoporosis, as well as the imbalance between bone formation and resorption. To date, four classes of agents are available: bisphosphonates, calcitonin, SERMS and denosumab. Two other drugs with unique mechanisms of action were either discontinued due to an unforeseen increase in stroke risk (odanacatib–cathepsin K inhibitor) or currently awaiting FDA's final licensing decision (romosozumab–sclerostin inhibitor that demonstrates both anabolic and anti-resorptive properties). Osteoanabolic agents have also proven to be a beneficial therapeutic option and can be combined with other active agents, particularly in patients classified as high fracture risk. As evidenced by current trials, osteoanabolic agents exhibit maximal effect when they precede anti-resorptive therapy. Moreover, while the combination of teriparatide and bisphosphonates does not appear to offer any additional benefit compared with monotherapy, results from the concurrent use of denosumab and teriparatide have been encouraging as additional BMD gains have been observed.

Despite the proven biochemical and clinical efficacy of established agents, the use of anti-osteoporosis drugs has been on the decline [113,114]. Indeed, widely disseminated issues of osteonecrosis of the jaw [115], atrial fibrillation and cardiovascular adverse events [116,117] may have contributed to this decline. However, the risk-benefit ratio of anti-osteoporotic therapy remains favourable [118] with some animal studies also showing potential in reducing arresting aortic valve and coronary artery calcification [119,120]. Recently, advances elucidating the cellular and molecular regulatory mechanisms of bone remodelling have spearheaded efforts to develop and establish novel therapies [121,122].

Traditional molecular techniques and animal models have been proven effective in identifying potential targets for new therapies; notwithstanding, a downturn in the number of new osteoporosis drugs has been observed. Abaloparatide, gaining approval by the FDA in April 2017, has been the first new anabolic anti-osteoporotic medication in the US for nearly 15 years. Considering the major breakthroughs achieved in the field of modern genetics, there may be more efficient ways in the quest for novel drug targets. Indeed, a recent retrospective analysis concluded that medications with direct genetic support demonstrated a significantly higher success rate across the drug developing pipeline [123].

The contribution of genetics in the coming years is looking promising, unveiling novel therapeutic targets in osteoporosis and providing an unprecedented understanding of the pathophysiological pathways underlying changes in BMD. Nonetheless, it is imperative to interrogate new phenotypes beyond BMD, for example, bone microarchitecture measured by quantitative computed tomography (QCT); shedding light on fracture risk and providing a better understanding of bone accrual and bone loss [124].

With the available spectrum of anti-resorptive drugs, the overall burden of osteoporosis could potentially be alleviated. However, low public awareness in addition to adverse-effect profile and lack of long-term fracture data have contributed to poor compliance and to a decline in the use of anti-osteoporotic drugs. There is a need for increasing public health awareness and healthcare provider education regarding screening, prevention and treatment of osteoporosis. In addition, the development of new pharmacological approaches that will fill unmet needs, specifically having a favourable safety profile, lacking the adverse effects of at AFFs and ONJ, employing a well-defined and simple dosing regimen and demonstrating long-term efficacy in reducing fracture rate or augmenting BMD, is deemed necessary.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

References

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. Rosen H, Drezner M. Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women - UpToDate [Internet]. 2018 [cited 2018 Nov 7]. Available from: https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-evaluation-of-osteoporosis-in-postmenopausal-women?search=osteoporosis&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3
2. Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in

the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013;75:392–396.

3. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359–2381.

4. Denosumab (Prolia). Denosumab treatment to increase bone mass men with osteoporosis high risk fracture or who have fail. or are intolerant to other available osteoporosis therapy. Ottawa(ON): Canadian Agency for Drugs and Technologies in Health; 2015.

5. Tsai J, Burnett-Bowie S, Lee H, et al. Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study. Bone. 2017;95:20–25.

6. Sapir-Koren R, Livshits G. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? Osteoporos Int. 2014;25:2685–2700.

7. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83:1032–1045.

8. Russell RGG. Bisphosphonates: from bench to bedside. Ann NY Acad Sci. 2006;1068:367–401.

9. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509–514.

10. Russell RGG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733–759.

11. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555–1565.

12. Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014;58:126–135.

13. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997;12:1700–1707.

14. Waalen J. Current and emerging therapies for the treatment of osteoporosis. J Exp Pharmacol. 2010;2:121.

15. Anagnostis P, Paschou SA, Mintziori G, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 2017;101:23–30.

16. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2016;31:16–35.

17. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–1249.

18. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet. 1996;348:1535–1541.

19. Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97:2272–2282.

20. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–1352.

21. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333–340.

22. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822.

23. Ensrud KE, Stock JL, Barrett-Connor E, et al. Effects of raloxifene on fracture risk in postmenopausal women: the raloxifene use for the heart trial. J Bone Miner Res. 2007;23:112–120.

24. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344:1434–1441.

25. Zhou J, Ma X, Wang T, et al. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016;27:3289–3300.
   • Network meta-analysis encompassing thirty six primary studies, comparing the efficacy of bisphosphonates.

26. Jansen JP, Bergman GJD, Huels J, et al. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011;40:275–284.e2.

27. Xu F, Teitelbaum S. Osteoclasts: new Insights. Bone Res. 2013;1:11–26.

28. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345–357.

29. Duong LT, Rodan GA. Regulation of osteoclast formation and function. Rev Endocr Metab Disord. 2001;2:95–104.

30. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis[1]. Endocr Rev. 2000;21:115–137.

31. Ross FP. M-CSF, c-Fms, and signaling in osteoclasts and their precursors. Ann NY Acad Sci. 2006;1068:110–116.

32. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9 Suppl 1:S1.

33. Bell NH. RANK ligand and the regulation of skeletal remodeling. J Clin Invest. 2003;111:1120–1122.

34. Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2015;11:461–470.

35. Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50:793–807.
   • Pooled analysis of 22944 serum denosumab concentrations defining pharmacokinetic properties of denosumab.

36. Mandema JW, Zheng J, Libanati C, et al. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response–based meta-analysis. J Clin Endocrinol Metab. 2014;99:3746–3755.
   •• Dose-response based meta-analysis including 142 RCTs.

37. Fontalis A, Kenanidis E, Prousali E, et al. Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2018;17:413–428.

38. Silverman SL, Siris E, Kendler DL, et al. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int. 2015;26:361–372.

39. Papaioannou A, Khan A, Belanger A, et al. Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program. Curr Med Res Opin. 2015;31:1391–1401.

40. Karlsson L, Lundkvist J, Psachoulia E, et al. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26:2401–2411.

41. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765.

42. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–523.

43. Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporos Int. 2016;27:1917–1921.

44. Lamy O, Gonzalez-Rodriguez E, Stoll D, et al. Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab. 2016;102:jc.2016–3170.

45. Anastasilakis AD, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int. 2016;27:1929–1930.
46. Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, et al. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int. 2016;27:1923–1925.
47. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–17.
48. Geller M, Wagman R, Ho P, et al. SAT0479 Early findings from Prolia® post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis. Ann Rheum Dis. 2014;73: 766.3–767.
49. Jilka R, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88–91.
50. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23: 279–302.
51. Copp DH, Cameron EC. Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract. Science. 1961; 134:2038.
52. Li J-Y, Chassaing B, Tyagi AM, et al. Sex steroid deficiency–associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest. 2016;126:2049–2063.
53. Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8:135–155.
54. Nelson ER, Wardell SE, McDonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis. Bone. 2013;53:42–50.
55. Migliaccio S, Brama M, Spera G. The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging. 2007;2:55–64.
56. Cosman F, Lindsay R. Selective estrogen receptor modulators. In: Henderson JE, Goltzman D, editors. Osteoporosis primer. Cambridge: Cambridge University Press; 2000. p. 291–303.
57. An K-C. Selective estrogen receptor modulators. Asian Spine J. 2016;10:787–791.
58. Palacios S. Selective estrogen receptor modulators: the future in menopausal treatment. Minerva Ginecol. 2011;63:275–286.
59. Gennari L, Merlotti D, Nuti R. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin Interv Aging. 2010;5:19–29.
60. NICE (National Institute for Health and Care excellence). Oestrogen deficiency symptoms in oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate. 2016.
61. Goldberg T, Fidler B. Conjugated estrogens/bazedoxifene (Duavee): a novel agent for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. P T. 2015;40:178–182.
62. Pickar JH, Boucher M, Morgenstern D. Tissue selective estrogen complex (TSEC): a review. Menopause. 2018;25:1033–1045.
63. Komm BS, Kharode YP, Bodine PVN, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146:3999–4008.
64. Palacios S. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Curr Med Res Opin. 2010;26: 1553–1563.
65. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–1934.
66. Palacios S, Silverman SL, de Villiers TJ, et al. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis. Menopause. 2015;22:806–813.
67. Gennari L, Merlotti D, Martini G, et al. Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opin Investig Drugs. 2006;15:1091–1103.
68. Gennari L, Merlotti D, De Paola V, et al. Lasofoxifene: evidence of its therapeutic value in osteoporosis. Core Evid. 2010;4:113–129.
69. Lewiecki EM. Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. Ther Clin Risk Manag. 2009;5:817–827.
70. Gardner M, Nishizawa Y, Wei G, et al. A single-dose pharmacokinetic study of lasofoxifene in Japanese and Caucasian postmenopausal women. J Bone Min Res. 2004;19 Abstract M469.
71. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362:686–696.
72. McClung M, Siris E, Cummings S, et al. Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD. J Bone Min Res. 2005;20:S97.
73. Vukicevic S, Grgurevi L. The PEARL trial: lasofoxifene and incidence of fractures, breast cancer and cardiovascular events in postmenopausal osteoporotic women. Int J Clin Rheumatol. 2011;6:387.
74. Eastell R, Reid DM, Vukicevic S, et al. The effects of lasofoxifene on bone turnover markers: the PEARL trial [abstract]. J Bone Min Res. 2008;23:1287.
75. Rachner TD, Hofbauer L, Göbel A, et al. Novel therapies in osteoporosis: PTH-related peptide analogues and inhibitors of sclerostin. J Mol Endocrinol. 2019;62:R145–R154.
76. Liu Y, Levack AE, Marty E, et al. Anabolic agents: what is beyond osteoporosis? Osteoporos Int. 2018;29:1009–1022.
77. Lewiecki EM, Miller PD. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. J Clin Densitom. 2013;16:28–32.
78. Leder BZ. Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy. Curr Osteoporos Rep. 2017;15:110–119.
79. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230–240.
80. Hattersley G, Dean T, Corbin BA, et al. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;157:141–149.
81. Varela A, Chouinard L, Lesage E, et al. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Bone. 2017;95:143–150.
82. Legrand J, Becret A, Fisch C, et al. BIM-44058, a novel PTHrP analog, increases bone formation but not bone resorption histomorphometric parameters in old ovariectomized cynomolgus monkeys. Twenty third Annual Meeting of the American Society of Bone and Mineral Research, Phoenix, Arizona, USA, October 12-16, 2001. J Bone Miner Res. 2011;16(suppl.1):S539.
83. Leder BZ, O'Dea LSL, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100:697–706.
84. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA. 2016;316:722.
85. FDA Approves Radius Health's TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture (NASDAQ:RDUS) [Internet]. 2017 [cited 2018 Apr 3]. Available from: http://investors.radiuspharm.com/releasedetail.cfm?ReleaseID=1023557
86. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207–1215.

87. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382:50–56.

88. Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103:2949–2957.

89. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353:555–565.

90. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009;24:726–736.

91. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93:852–860.

92. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23:1591–1600.

93. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585–1594.

94. Poole KES, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842–1844.

95. Chan CKY, Mason A, Cooper C, et al. Novel advances in the treatment of osteoporosis. Br Med Bull. 2016;119:129–142.

96. Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. Carvalho DP de, editor. PLoS One. 2011;6:e25900.

97. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537–543.

98. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578–588.

99. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25:948–959.

100. Lim SY, Bolster MB. Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Devel Ther. 2017;11:1221–1231.

101. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19–26.

102. Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014;54:168–178.

103. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412–420.

104. Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30:216–224.

105. Keaveny TM, Crittenden DB, Bolognese MA, et al. Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32:1956–1962.

106. Lewiecki E, Horlait S, Blicharski T, et al. Results of a phase 3 clinical trial to evaluate the efficacy and safety of romosozumab in men with osteoporosis - ACR meeting abstracts. Abstract Supplement. Arthritis Rheumatol. 2016;68:1–4550.

107. Albanese I, Khan K, Barratt B, et al. Atherosclerotic calcification: Wnt is the hint. J Am Heart Assoc. 2018;7:e007356.

108. Evenepoel P, D'Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int. 2015;88:235–240.

109. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–1543.

110. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–1427.

111. Ge X, Wang X. Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol. 2010;3:33.

112. EVENITY romosozumab receives approval in Japan for the treatment of osteoporosis in patients at high risk of fracture [Internet]. [cited 2019 Feb 15]. Available from: https://www.amgen.com/media/news-releases/2019/01/evenity-romosozumab-receives-approval-in-japan-for-the-treatment-of-osteoporosis-in-patients-at-high-risk-of-fracture/

113. Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29:1929–1937.

114. Kanis JA, Svedbom A, Harvey N, et al. The osteoporosis treatment gap. J Bone Miner Res. 2014;29:1926–1928.

115. Lee S-H, Chang -S-S, Lee M, et al. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis. Osteoporos Int. 2014;25:1131–1139.

116. Kim DH, Rogers JR, Fulchino LA, et al. Bisphosphonates and risk of cardiovascular events: a meta-analysis. Pizzi C, editor. PLoS One. 2015;10:e0122646.

117. Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke. 2009;40:147–155.

118. Reyes C, Hitz M, Prieto-Alhambra D, et al. Risks and benefits of bisphosphonate therapies. J Cell Biochem. 2016;117:20–28.

119. Synetos A, Toutouzas K, Drakopoulou M, et al. Inhibition of aortic valve calcification by local delivery of zoledronic acid-an experimental study. J Cardiovasc Transl Res. 2018;11:192–200.

120. Synetos A, Toutouzas K, Benetos G, et al. Catheter based inhibition of arterial calcification by bisphosphonates in an experimental atherosclerotic rabbit animal model. Int J Cardiol. 2014;176:177–181.

121. Taipaleenmäki H. Regulation of bone metabolism by microRNAs. Curr Osteoporos Rep. 2018;16:1–12.

122. Kenkre JS, Bassett J. The bone remodelling cycle. Ann Clin Biochem. 2018;55:308–327.

123. Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–860.

124. Sabik OL, Farber CR. Using GWAS to identify novel therapeutic targets for osteoporosis. Transl Res. 2017;181:15–26.